A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

被引：6
|
作者：
Choi, Jae Duk
Baek, Seungjae
Kim, Youngmin
Eun, Kahee
Kwon, Se Chang
Morrow, Linda
Hompesch, Marcus
Kang, Jahoon
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-982-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
982-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A randomized, double-blinded, placebo-controlled single ascending dose study to assess safety, tolerability, immunogenicity, and pharmacokinetics of a novel long-acting GLP-1/GIP/glucagon triple agonist (hm15211) in healthy obese subjects
    Choi, JaeDuk
    Kim, Youngmin
    Eun, Kahee
    Morrow, Linda
    Hompesch, Marcus
    Baek, Seungjae
    JOURNAL OF HEPATOLOGY, 2020, 73 : S455 - S456
  • [2] Effect of a novel long-acting GLP-1/GIP/glucagon triple agonist (HM15211) in a dyslipidaemia animal models
    Jo, H.
    Kim, J.
    Choi, J.
    Lee, S.
    Lee, S. -H.
    Choi, I.
    DIABETOLOGIA, 2019, 62 : S510 - S511
  • [3] Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/glucagon triple agonist in the neurodegenerative disease models
    Kim, J.
    Lee, S.
    Lee, S. -H.
    Jung, S.
    Kim, Y.
    Choi, I.
    Kim, S.
    DIABETOLOGIA, 2018, 61 : S84 - S85
  • [4] Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis
    Kim, Jung Kuk
    Lee, Jong Suk
    Lee, Seon Myeong
    Kwon, Hyunjoo
    Choi, Jaehyuk
    Park, Eunjin
    Bae, Sungmin
    Kim, Daejin
    Kim, Young Hoon
    Choi, In Young
    DIABETES, 2021, 70
  • [5] Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF
    Kim, Jeong A.
    Lee, Jong Suk
    Kim, Jung Kuk
    Ban, Young-Hwan
    Lee, Jongsoo
    Bae, Sungmin
    Kim, Daejin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2022, 71
  • [6] Neuroprotective effects of HM15211, a novel long-acting GLP-1/GIP/Glucagon triple agonist in the neurodegenerative disease models
    Kim, W.
    Kim, J.
    Lee, S. -H.
    Bae, S.
    Choi, I.
    Kim, Y.
    DIABETOLOGIA, 2019, 62 : S292 - S292
  • [7] Bone Protective Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in an Animal Model
    Lee, Sangdon
    Kim, Yu-Yon
    Lee, Jong Suk
    Lee, Sang Hyun
    Kim, Young Hoon
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [8] Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a Dyslipidemia Animal Model
    Choi, Jaehyuk
    Jo, Hyosang
    Kim, Jung Kuk
    Lee, Sang Don
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2019, 68
  • [9] Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models
    Kim, Jeong A.
    Lee, Sangdon
    Lee, Sang Hyun
    Jung, Sung Youb
    Kim, Young Hoon
    Choi, In Young
    Kim, Sun Jin
    DIABETES, 2018, 67
  • [10] Bone protective effect of a novel long-acting GLP-1/GIP/Glucagon triple agonist (HM15211) in an animal model
    Lee, S.
    Kim, Y. -Y.
    Lee, J.
    Lee, S. -H.
    Kim, Y.
    Choi, I.
    Kim, S.
    DIABETOLOGIA, 2018, 61 : S244 - S245
12345